Results 11 to 20 of about 8,070,232 (284)

Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study [PDF]

, 2013
Background: The clinical management of pancreatic cancer is severely hampered by the absence of effective screening tools. Methods: Sixty-seven biomarkers were evaluated in prediagnostic sera obtained from cases of pancreatic cancer enrolled in the ...
Aleksey Lomakin, Anna E Lokshin, Brian M Nolen, Denise Prosser, Herbert J Zeh, Liudmila Velikokhatnaya, Peter J Allen, Randall E Brand, William E Grizzle, Ying Huang   +9 more
core   +7 more sources

CA 19-9 and CA 125 Determination by Immunoluminometric Assay [PDF]

Clinical Chemistry and Laboratory Medicine, 1990
We evaluated a new immunoluminometric technique (ILMA) for the measurement of the cancer antigens, CA 19-9 and CA 125 in serum. A satisfactory reproducibility was found, coefficients of variation ranging from 4.2 to 7.3% in within-run and between-run assays. The linearity of tests was maintained over a wide concentration range. Mean analytical recovery
PLEBANI, MARIO, FAGGIAN, DIEGO, MASIERO, MASSIMO, Giacomini A, Burlina A.   +4 more
openaire   +4 more sources

Clinical significance and revisiting the meaning of CA 19-9 blood level before and after the treatment of pancreatic ductal adenocarcinoma: analysis of 1,446 patients from the pancreatic cancer cohort in a single institution. [PDF]

PLoS ONE, 2013
BACKGROUND: Life expectancy of pancreatic ductal adenocarcinoma (PDAC) patients is usually short and selection of the most appropriate treatment is crucial.
Joo Kyung Park, Woo Hyun Paik, Ji Kon Ryu, Yong-Tae Kim, Youn Joo Kim, Jaihwan Kim, Byeong Jun Song, Jin Myung Park, Yong Bum Yoon   +8 more
doaj   +1 more source

Predicting Adverse Pathologic Features and Clinical Outcomes of Resectable Pancreas Cancer With Preoperative CA 19-9

Frontiers in Oncology, 2021
BackgroundWe evaluated preoperative CA 19-9 levels in patients with resected pancreatic cancer to analyze whether they were predictive of clinical outcomes and could help select patients for additional therapy. We hypothesized that elevated CA 19-9 would
Roman O. Kowalchuk, Scott C. Lester, Rondell P. Graham, William S. Harmsen, Lizhi Zhang, Thorvardur R. Halfdanarson, Rory L. Smoot, Hunter C. Gits, Wen Wee Ma, Dawn Owen, Amit Mahipal, Robert C. Miller, Michelle A. Neben Wittich, Sean P. Cleary, Robert R. McWilliams, Michael G. Haddock, Christopher L. Hallemeier, Mark J. Truty, Kenneth W. Merrell   +18 more
doaj   +1 more source

Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer [PDF]

, 2006
In pancreatic cancer ( PC) accurate determination of treatment response by imaging often remains difficult. Various efforts have been undertaken to investigate new factors which may serve as more appropriate surrogate parameters of treatment efficacy ...
Anderson JS, Bekaii-Saab TS, Brambs HJ, Burris HA, Ebrahimi B, Glenn J, Gogas H, Goggins M, Heinemann V, Heinemann V, Heinemann V, Ishii H, Jamieson NB, Jiang XT, Katz A, Ko AH, Koprowski H, Louvet C, Lundin J, Maisey NR, Montgomery RC, Moore MJ, Ni XG, Okusaka T, Petra Stieber, Philip PA, Ralf Wilkowski, Saad ED, Safi F, Safi F, Sakar B, Sawaki A, Sperti C, Stathopoulos GP, Stefan Boeck, Stefan Holdenrieder, Steinberg W, Tanaka N, Tempero MA, Tian F, van Custem E, Vimalachandran D, Volker Heinemann, Wilkowski R, Wilkowski R, Wilkowski R, Willet CG, Wolff RA, Ziske C   +48 more
core   +1 more source

Yüksek Serum CA19-9 Seviyeleri ile Seyreden Bir Endometriozis Olgusu

Sakarya Tıp Dergisi, 2019
CA19-9 özellikle safra kanalı ve pankreas kanserlerinde yüksek olarak saptanan bir tümör belirtecidir. Bu durumlara ek olarak kolon, mide, over, karaciğer ve özafagus kanserleri gibi diğer malign durumlarda da yüksek seviyelerde saptanır.CA19-9 pankreas ...
Özlem Nuray Sever, Dilahan Şankır
doaj   +1 more source

High Carbohydrate 19-9 Antigen Serum Levels in Patients with Nonmelanoma Skin Cancer and Primary Occult Cancer

Biomedicines, 2020
Background: Non-melanoma skin cancers (NMSC), despite having a favourable prognosis, present an increased risk of occult malignancies. The aim of this study was the evaluation of the usefulness of the mucinous marker carbohydrate 19-9 antigen (CA 19-9 ...
Giulia Malaguarnera, Saverio Latteri, Roberto Madeddu, Vito Emanuele Catania, Gaetano Bertino, Rosario Emanuele Perrotta, Francesco Dinotta, Michele Malaguarnera   +7 more
doaj   +1 more source

Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin? [PDF]

, 2003
Background: Serial kinetics of serum CA 19-9 levels have been reported to reflect response and survival in patients with pancreatic cancer undergoing surgery, radiotherapy, and chemotherapy.
Garbrecht, M., Heinemann, Volker, Helmberger, T., Lamerz, Rolf, Niebler, K., Schalhorn, A., Schermuly, M. M., Stemmler, J., Stieber, P., Stoffregen, C., Szymala, A. M., Wilkowski, R.   +11 more
core   +1 more source

Assessing prognosis in metastatic pancreatic cancer by the serum tumor marker CA 19-9: Pretreatment levels or kinetics during chemotherapy? [PDF]

, 2007
Background: The carbohydrate antigen 19-9 (CA 19-9) is currently the most widely used serum tumor marker in pancreatic cancer (PC). CA 19-9 pretreatment levels as well as CA 19-9 kinetics during systemic chemotherapy can provide prognostic information ...
Boeck, Stefan, Heinemann, Volker, Holdenrieder, Stefan, Schulz, Christoph, Stieber, Petra, Weckbach, Sabine   +5 more
core   +1 more source

Metastatc Gastric Adenocarcinoma Cancer With a Very High Serum Carbohydrate Antgen 19-9 Level: A Case Study

Case Reports in Clinical Practice, 2021
Carbohydrate Antigen 19-9 (CA19-9) is a tumor marker for the prognosis of colorectal and pancreatic cancers. The high level of this tumor marker in gastric cancer indicates the advanced stage and peritoneal metastasis of the tumor.
Alireza Jafarinezhad, Neda Aligolighasemabadi   +1 more
doaj   +1 more source